venBio Partners’s Verona Pharma VRNA Stock Holding History

venBio Partners’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-161,897	Closed	-$678K	–	9
2022 Q2	$678K	Hold	161,897	–	–	0.19%	9
2022 Q1	$808K	Hold	161,897	–	–	0.18%	10
2021 Q4	$1.09M	Hold	161,897	–	–	0.2%	9
2021 Q3	$887K	Hold	161,897	–	–	0.09%	9
2021 Q2	$1.06M	Hold	161,897	–	–	0.13%	10
2021 Q1	$1.35M	Sell	161,897 -37,178	-19%	-$308K	0.13%	8
2020 Q4	$1.39M	Hold	199,075	–	–	0.12%	7
2020 Q3	$1.24M	Sell	199,075 -257,695	-56%	-$1.78M	0.19%	8
2020 Q2	$2.14M	Hold	456,770	–	–	1.78%	4
2020 Q1	$1.88M	Sell	456,770 -418,230	-48%	-$2.3M	1.6%	6
2019 Q4	$5.03M	Hold	875,000	–	–	2.16%	6
2019 Q3	$4M	Hold	875,000	–	–	1.9%	6
2019 Q2	$4.46M	Hold	875,000	–	–	1.98%	6
2019 Q1	$5.69M	Hold	875,000	–	–	4.61%	4
2018 Q4	$8.44M	Hold	875,000	–	–	22.18%	2
2018 Q3	$10.9M	Hold	875,000	–	–	19.15%	3
2018 Q2	$12M	Hold	875,000	–	–	12.33%	2
2018 Q1	$17.5M	Hold	875,000	–	–	10.79%	3
2017 Q4	$10.4M	Buy	+875,000	New	+$11.4M	10.31%	3

Other funds holding VRNA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

venBio Partners's VRNA Position: Q3 2022 in Review

venBio Partners sold out of Verona Pharma (VRNA) in Q3 2022, closing a stake of 161,897 shares — an estimated $678K sold.

venBio Partners first reported a position in VRNA in Q4 2017 and held it in 19 quarters. The position peaked at $17.5M in Q1 2018. 68 funds tracked by Wall St. Rank hold VRNA as of Q3 2022.

venBio Partners reported no remaining Verona Pharma position as of Q3 2022 after selling out during the quarter.
venBio Partners sold 161,897 Verona Pharma shares in Q3 2022, an estimated $678K.
venBio Partners first reported a position in Verona Pharma in Q4 2017 and held it in 19 quarters.
venBio Partners's Verona Pharma position peaked at $17.5M in Q1 2018.
68 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2022.

Based on venBio Partners's 13F filing for Q3 2022, filed 14 Nov 2022.